Dear Readers,
This has been an exciting year for us, as we changed our name to NEJM Journal Watch Cardiology. We remain devoted to providing clinicians with the information they need to provide their patients with the best care — and, as part of NEJM Group, we are now poised to do that better than ever.
The year ended with a lot of attention on the new lipid guidelines, and they are at the top of our list. Much-anticipated, long-delayed, and ultimately controversial, the guidelines retired lipid targets as a way to guide therapy and refocused patients and doctors on risk assessment and the potential benefit and use of medications proven to improve outcomes. Controversy rages about the risk calculator and thresholds for treatment, but the gene…
Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association